Diagnostic Workup, Biopsy, Imaging, and Pathology Basics
Key Takeaways
- Cancer diagnosis usually requires tissue or cytology confirmation; imaging and labs define extent, complications, and treatment readiness.
- Biopsy planning weighs safest access, adequate tissue for pathology and biomarkers, bleeding risk, anticoagulants, and infection risk.
- Pathology reports may include histology, grade, margins, lymphovascular invasion, receptor status, and molecular markers.
- Imaging modalities answer different questions; the nurse coordinates preparation, contrast safety screening, and result follow-up.
- Tumor markers such as PSA, CA-125, CEA, AFP, and CA 19-9 support monitoring in select cancers but are not stand-alone screening tests.
Diagnostic Workup, Biopsy, Imaging, and Pathology Basics
Diagnostic Thinking in Oncology Nursing
The diagnostic workup answers linked questions: Is cancer present? What type? Where did it start? How far has it spread? Which biomarkers guide therapy? Is the patient safe for the planned procedure? The OCN focuses on assessment, education, specimen awareness, coordination, and complication recognition. A critical boundary: the nurse does not tell a patient they have cancer before provider disclosure, but can explain planned tests and reduce delays. The diagnostic phase is also when uncertainty and anxiety peak, so the nurse manages waiting, clarifies the sequence of tests, and screens for distress while results are pending.
Tissue Diagnosis and Biopsy
Most solid cancers require tissue or cytology confirmation. Biopsy choices depend on suspected type, location, the need for intact architecture, tissue volume for biomarker panels, and procedural risk.
| Biopsy type | What it provides | Common use |
|---|---|---|
| Fine-needle aspiration (FNA) | Cells only (cytology) | Thyroid nodule, palpable node |
| Core needle | Tissue core with architecture | Breast, prostate, liver |
| Excisional | Entire lesion | Small node, suspicious lymph node |
| Incisional | Part of a large lesion | Soft-tissue sarcoma |
| Endoscopic | Tissue from a mucosal surface | Colorectal, gastric, lung |
| Bone marrow aspiration/biopsy | Marrow cells and architecture | Leukemia, lymphoma staging |
Nursing preparation confirms allergies, anticoagulant and antiplatelet use, bleeding history, pregnancy status, renal function for contrast, infection symptoms, sedation and transportation plans, and a baseline pain and neurologic exam. Teaching covers purpose, positioning, expected sensations, post-procedure activity limits, when results return, and which symptoms to report.
Post-biopsy complications by site: lung biopsy can cause pneumothorax or hemoptysis; liver biopsy, bleeding or referred right-shoulder pain; bone marrow, localized pain or bleeding; lumbar puncture, post-dural-puncture headache. Escalate dyspnea, chest pain, expanding swelling, uncontrolled bleeding, fever, severe pain, syncope, new weakness, or mental-status change.
Imaging Basics
| Modality | Common oncology use | Nursing considerations |
|---|---|---|
| Computed tomography (CT) | Anatomy, staging, response, complications | Iodinated-contrast allergy, renal function (eGFR), hydration, metformin policy per site |
| Magnetic resonance imaging (MRI) | Brain, spine, pelvis, liver, soft tissue | Implant/pacemaker screening, claustrophobia, gadolinium and renal caution |
| PET/CT (positron emission tomography) | Metabolic activity, staging, recurrence | Fasting, glucose under ~150-200 mg/dL, inflammation causes false positives |
| Ultrasound | Thyroid, breast, liver, fluid guidance | Procedure prep, biopsy guidance, ascites evaluation |
| Bone scan | Osteoblastic bone activity | Hydration, delayed imaging, arthritis/fracture false positives |
| Mammography | Breast screening and diagnosis | Prior images, compression teaching, follow-up coordination |
Key safety teaching: PET uses radiolabeled glucose (fluorodeoxyglucose), so elevated blood glucose can blunt tumor uptake; hold metformin per site policy after iodinated contrast because of lactic-acidosis risk if renal function declines; and screen every MRI patient for implanted metal.
Pathology Report Literacy
A pathology report may include specimen site, histologic type, tumor size, grade, margin status, lymphovascular and perineural invasion, lymph-node involvement, receptor status, immunohistochemistry, and molecular findings. A breast report often lists invasive ductal carcinoma, Nottingham grade, ER/PR/HER2, Ki-67 proliferation index, margins, and nodes. A colorectal report often lists adenocarcinoma, depth of invasion, nodes, margins, lymphovascular invasion, and mismatch-repair status.
Histology names the tissue pattern: adenocarcinoma, squamous cell carcinoma, small cell carcinoma, melanoma, sarcoma, lymphoma, leukemia, glioma, or germ cell tumor. Cytology evaluates loose cells without full architecture and may be sufficient (thyroid FNA) or insufficient (when grading and invasion matter). The nurse recognizes when more tissue is needed for biomarkers and helps obtain outside slides or blocks.
Laboratory and Tumor Markers
Common adjuncts: complete blood count, comprehensive metabolic panel, liver and renal function, coagulation studies, lactate dehydrogenase (LDH), and disease-specific markers. Tumor markers support monitoring more than screening:
| Marker | Associated cancer |
|---|---|
| PSA (prostate-specific antigen) | Prostate |
| CA-125 | Ovarian |
| CEA (carcinoembryonic antigen) | Colorectal |
| AFP (alpha-fetoprotein) | Hepatocellular, germ cell |
| CA 19-9 | Pancreatic |
| Beta-hCG | Germ cell, gestational trophoblastic |
Markers can rise from benign conditions and are interpreted as trends by the oncology team. The OCN reduces harm by tracking pending pathology, confirming imaging appointments, ensuring contrast instructions are understood, and escalating urgently for airway compromise, cord-compression symptoms, SVC syndrome signs, sepsis, uncontrolled bleeding, or unstable labs.
Contrast Safety and Pre-Procedure Verification
Contrast safety is a frequent OCN test point. Before iodinated CT contrast, verify renal function (estimated glomerular filtration rate), screen for prior contrast reactions, and follow institutional metformin policy because of the rare risk of lactic acidosis if kidney function falls. Before gadolinium MRI contrast, severe renal impairment raises the risk of nephrogenic systemic fibrosis, so renal function is again checked.
For any biopsy, the nurse confirms the patient has held anticoagulants and antiplatelets per orders, verifies platelet count and coagulation studies, confirms consent, performs a timeout, and reviews the post-procedure monitoring plan. After image-guided procedures, the nurse monitors the site, vital signs, and pain, and provides clear instructions on warning signs and whom to call. These verification habits prevent both procedural harm and delays in starting time-sensitive treatment.
A frequent OCN trap is the patient on a direct oral anticoagulant or low-molecular-weight heparin who was not told to hold it; the nurse confirms the hold window and reschedules rather than proceeding with elevated bleeding risk.
A patient develops sudden shortness of breath and pleuritic chest pain immediately after a CT-guided lung biopsy. What should the nurse suspect and do first?
Which pathology element most directly describes whether tumor extends to the cut edge of a resected specimen?
Which teaching point about PET/CT is most accurate?